The specter of generic rivalry has consistently loomed around copyright’s famous drug, PDE5 Inhibitor, triggering questions about the outlook of similar drug portfolios. While early periods saw impressive gains, the intellectual property end has allowed the way for discounted alternatives, potentially lowering profitability and creating a genuine